Digestive System Neuroendocrine Neoplasm
Associated Genetic Biomarkers
NCI Definition: A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas). 
Digestive system neuroendocrine neoplasms most frequently harbor alterations in TP53, APC, KRAS, RB1, and CDKN1B .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, APC Mutation, and KRAS Mutation are the most common alterations in digestive system neuroendocrine neoplasm .
There are 3 clinical trials for digestive system neuroendocrine neoplasm, of which 3 are open and 0 are completed or closed. Of the trials that contain digestive system neuroendocrine neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).
SSTR1, SSTR2, and SSTR3 are the most frequent gene inclusion criteria for digestive system neuroendocrine neoplasm clinical trials .
Atezolizumab, cabozantinib, and lanreotide are the most common interventions in digestive system neuroendocrine neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.